

Chemotherapy agents - AntiMetabolites: All cancers
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		12596	134	1.1	183	1.5	3117	24.8	68	0.5	4	0.0	3966	31.5	5664	45.0	1176	9.3
	Age at baseline	<18	3606	25	0.7	88	2.4	1349	37.4	22	0.6	1	0.0	1467	40.7	1792	49.7	505	14.0
		18-19	1112	11	1.0	20	1.8	337	30.3	6	0.5	.	.	467	42.0	591	53.2	116	10.4
		20-24	2665	37	1.4	35	1.3	635	23.8	16	0.6	1	0.0	938	35.2	1325	49.8	211	7.9
		25-29	2406	33	1.4	27	1.1	481	20.0	10	0.4	1	0.0	667	27.8	1073	44.7	205	8.5
		30-34	1697	17	1.0	10	0.6	226	13.3	10	0.6	1	0.1	305	18.0	618	36.5	94	5.5
		35+	1110	11	1.0	3	0.3	89	8.1	4	0.4	.	.	122	11.1	265	24.0	45	4.1
	Years since diagnosis	5-9	1932	18	0.9	45	2.3	794	41.1	19	1.0	2	0.1	673	34.9	990	51.3	304	15.7
		10-14	4649	36	0.8	96	2.1	1376	29.6	24	0.5	2	0.0	1526	32.9	2211	47.6	540	11.6
		15-19	3456	44	1.3	37	1.1	624	18.1	21	0.6	.	.	1070	31.0	1535	44.5	220	6.4
		20+	2559	36	1.4	5	0.2	323	12.7	4	0.2	.	.	697	27.3	928	36.4	112	4.4
	Age at diagnosis	<1	882	1	0.1	18	2.0	92	10.4	7	0.8	.	.	64	7.3	93	10.6	44	5.0
		1-4	4186	44	1.1	74	1.8	1338	32.0	13	0.3	.	.	2022	48.3	2337	55.8	441	10.5
		5-9	2777	44	1.6	29	1.0	821	29.6	13	0.5	.	.	1083	39.1	1458	52.6	293	10.6
		10-14	2531	30	1.2	43	1.7	552	21.9	19	0.8	1	0.0	557	22.1	1086	43.0	263	10.4
		15-20	2220	15	0.7	19	0.9	314	14.2	16	0.7	3	0.1	240	10.8	690	31.2	135	6.1
	Treatment	Chemotherapy, no radiation	3091	14	0.5	96	3.1	968	31.3	9	0.3	1	0.0	1112	36.0	1913	61.9	325	10.5
		Chemotherapy and radiation	7024	120	1.7	86	1.2	2138	30.4	59	0.8	3	0.0	2843	40.5	3734	53.2	848	12.1
Males	All cases		6650	69	1.0	88	1.3	1762	26.5	35	0.5	1	0.0	2089	31.5	3107	46.8	697	10.5
	Age at baseline	<18	1919	16	0.8	45	2.3	773	40.3	9	0.5	.	.	798	41.6	988	51.5	298	15.5
		18-19	606	5	0.8	9	1.5	201	33.2	6	1.0	.	.	248	40.9	336	55.4	83	13.7
		20-24	1380	19	1.4	13	0.9	331	24.0	5	0.4	1	0.1	462	33.5	678	49.2	116	8.4
		25-29	1331	18	1.4	12	0.9	288	21.7	6	0.5	.	.	363	27.3	621	46.7	128	9.6
		30-34	886	8	0.9	8	0.9	132	14.9	7	0.8	.	.	156	17.6	343	38.8	55	6.2
		35+	528	3	0.6	1	0.2	37	7.1	2	0.4	.	.	62	11.8	141	26.9	17	3.2
	Years since diagnosis	5-9	1073	13	1.2	23	2.1	486	45.3	11	1.0	1	0.1	389	36.3	581	54.1	191	17.8
		10-14	2495	16	0.6	48	1.9	779	31.2	14	0.6	.	.	816	32.7	1238	49.7	323	13.0
		15-19	1764	26	1.5	15	0.9	330	18.7	8	0.5	.	.	522	29.6	794	45.1	119	6.8
		20+	1318	14	1.1	2	0.2	167	12.7	2	0.2	.	.	362	27.6	494	37.6	64	4.9
	Age at diagnosis	<1	446	1	0.2	9	2.0	40	9.0	2	0.4	.	.	26	5.8	39	8.8	20	4.5
		1-4	2174	20	0.9	34	1.6	747	34.4	5	0.2	.	.	1054	48.5	1235	56.8	262	12.1
		5-9	1548	27	1.7	15	1.0	476	30.8	6	0.4	.	.	580	37.5	829	53.6	194	12.5
		10-14	1315	13	1.0	15	1.1	299	22.8	14	1.1	.	.	280	21.3	580	44.2	139	10.6
		15-20	1167	8	0.7	15	1.3	200	17.2	8	0.7	1	0.1	149	12.8	424	36.5	82	7.1
	Treatment	Chemotherapy, no radiation	1570	6	0.4	39	2.5	484	30.8	515	32.8	974	62.0	167	10.6
		Chemotherapy and radiation	3810	63	1.7	48	1.3	1272	33.4	35	0.9	1	0.0	1568	41.2	2122	55.7	529	13.9
Females	All cases		5946	65	1.1	95	1.6	1355	22.8	33	0.6	3	0.1	1877	31.6	2557	43.1	479	8.1
	Age at baseline	<18	1687	9	0.5	43	2.6	576	34.2	13	0.8	1	0.1	669	39.7	804	47.7	207	12.3

		18-19	506	6	1.2	11	2.2	136	26.9	219	43.4	255	50.5	33	6.5
		20-24	1285	18	1.4	22	1.7	304	23.7	11	0.9	.	.	476	37.0	647	50.4	95	7.4
		25-29	1075	15	1.4	15	1.4	193	18.0	4	0.4	1	0.1	304	28.3	452	42.1	77	7.2
		30-34	811	9	1.1	2	0.2	94	11.6	3	0.4	1	0.1	149	18.4	275	34.0	39	4.8
		35+	582	8	1.4	2	0.3	52	9.0	2	0.3	.	.	60	10.4	124	21.4	28	4.8
	Years since diagnosis	5-9	859	5	0.6	22	2.6	308	35.9	8	0.9	1	0.1	284	33.1	409	47.7	113	13.2
		10-14	2154	20	0.9	48	2.2	597	27.7	10	0.5	2	0.1	710	33.0	973	45.2	217	10.1
		15-19	1692	18	1.1	22	1.3	294	17.4	13	0.8	.	.	548	32.4	741	43.8	101	6.0
		20+	1241	22	1.8	3	0.2	156	12.6	2	0.2	.	.	335	27.1	434	35.1	48	3.9
	Age at diagnosis	<1	436	.	.	9	2.1	52	11.9	5	1.1	.	.	38	8.7	54	12.4	24	5.5
		1-4	2012	24	1.2	40	2.0	591	29.4	8	0.4	.	.	968	48.1	1102	54.8	179	8.9
		5-9	1229	17	1.4	14	1.1	345	28.1	7	0.6	.	.	503	41.0	629	51.3	99	8.1
		10-14	1216	17	1.4	28	2.3	253	20.8	5	0.4	1	0.1	277	22.8	506	41.7	124	10.2
		15-20	1053	7	0.7	4	0.4	114	10.9	8	0.8	2	0.2	91	8.7	266	25.4	53	5.1
	Treatment	Chemotherapy, no radiation	1521	8	0.5	57	3.7	484	31.8	9	0.6	1	0.1	597	39.3	939	61.7	158	10.4
		Chemotherapy and radiation	3214	57	1.8	38	1.2	866	26.9	24	0.7	2	0.1	1275	39.7	1612	50.2	319	9.9

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: All leukemias
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4276	76	1.8	181	4.2	2488	58.2	4	0.1	3	0.1	3680	86.1	4121	96.4	917	21.4
	Age at baseline	<18	1636	18	1.1	87	5.3	1163	71.1	3	0.2	1	0.1	1425	87.1	1573	96.1	454	27.8
		18-19	503	7	1.4	20	4.0	271	53.9	1	0.2	.	.	447	88.9	484	96.2	88	17.5
		20-24	999	26	2.6	35	3.5	504	50.5	874	87.5	977	97.8	164	16.4
		25-29	714	17	2.4	26	3.6	355	49.7	.	.	1	0.1	592	82.9	688	96.4	138	19.3
		30-34	309	6	1.9	10	3.2	142	46.0	.	.	1	0.3	244	79.0	289	93.5	47	15.2
		35+	115	2	1.7	3	2.6	53	46.1	98	85.2	110	95.7	26	22.6
	Years since diagnosis	5-9	784	12	1.5	44	5.6	633	80.7	3	0.4	1	0.1	636	81.1	736	93.9	266	33.9
		10-14	1679	19	1.1	95	5.7	1116	66.5	.	.	2	0.1	1431	85.2	1618	96.4	435	25.9
		15-19	1096	24	2.2	37	3.4	491	44.8	1	0.1	.	.	984	89.8	1068	97.4	138	12.6
		20+	717	21	2.9	5	0.7	248	34.6	629	87.7	699	97.5	78	10.9
	Age at diagnosis	<1	87	.	.	18	20.7	72	82.8	1	1.1	.	.	60	69.0	77	88.5	38	43.7
		1-4	2204	38	1.7	74	3.4	1205	54.7	2	0.1	.	.	1982	89.9	2145	97.3	395	17.9
		5-9	1109	26	2.3	28	2.5	625	56.4	1	0.1	.	.	982	88.5	1086	97.9	219	19.7
		10-14	592	8	1.4	42	7.1	387	65.4	.	.	1	0.2	463	78.2	554	93.6	180	30.4
		15-20	284	4	1.4	19	6.7	199	70.1	.	.	2	0.7	193	68.0	259	91.2	85	29.9
	Treatment	Chemotherapy, no radiation	1302	9	0.7	96	7.4	786	60.4	1	0.1	1	0.1	1058	81.3	1197	91.9	261	20.0
		Chemotherapy and radiation	2955	67	2.3	84	2.8	1692	57.3	3	0.1	2	0.1	2611	88.4	2910	98.5	653	22.1
Males	All cases		2221	40	1.8	87	3.9	1343	60.5	3	0.1	.	.	1898	85.5	2140	96.4	523	23.5
	Age at baseline	<18	882	11	1.2	45	5.1	652	73.9	2	0.2	.	.	768	87.1	845	95.8	263	29.8
		18-19	268	3	1.1	9	3.4	155	57.8	1	0.4	.	.	236	88.1	257	95.9	60	22.4
		20-24	485	13	2.7	13	2.7	243	50.1	421	86.8	475	97.9	85	17.5
		25-29	383	10	2.6	11	2.9	197	51.4	311	81.2	369	96.3	81	21.1
		30-34	153	2	1.3	8	5.2	78	51.0	117	76.5	146	95.4	27	17.6
		35+	50	1	2.0	1	2.0	18	36.0	45	90.0	48	96.0	7	14.0
	Years since diagnosis	5-9	441	8	1.8	23	5.2	369	83.7	2	0.5	.	.	361	81.9	419	95.0	163	37.0
		10-14	888	8	0.9	47	5.3	602	67.8	752	84.7	854	96.2	247	27.8
		15-19	534	15	2.8	15	2.8	252	47.2	1	0.2	.	.	471	88.2	518	97.0	72	13.5
		20+	358	9	2.5	2	0.6	120	33.5	314	87.7	349	97.5	41	11.5
	Age at diagnosis	<1	38	.	.	9	23.7	31	81.6	25	65.8	33	86.8	16	42.1
		1-4	1149	17	1.5	34	3.0	660	57.4	2	0.2	.	.	1029	89.6	1113	96.9	228	19.8
		5-9	583	16	2.7	15	2.6	347	59.5	1	0.2	.	.	512	87.8	569	97.6	144	24.7
		10-14	278	4	1.4	14	5.0	182	65.5	216	77.7	265	95.3	81	29.1
		15-20	173	3	1.7	15	8.7	123	71.1	116	67.1	160	92.5	54	31.2
	Treatment	Chemotherapy, no radiation	598	4	0.7	39	6.5	356	59.5	478	79.9	546	91.3	124	20.7
		Chemotherapy and radiation	1611	36	2.2	47	2.9	982	61.0	3	0.2	.	.	1414	87.8	1586	98.4	398	24.7
Females	All cases		2055	36	1.8	94	4.6	1145	55.7	1	0.0	3	0.1	1782	86.7	1981	96.4	394	19.2

	Age at baseline	<18	754	7	0.9	42	5.6	511	67.8	1	0.1	1	0.1	657	87.1	728	96.6	191	25.3
		18-19	235	4	1.7	11	4.7	116	49.4	211	89.8	227	96.6	28	11.9
		20-24	514	13	2.5	22	4.3	261	50.8	453	88.1	502	97.7	79	15.4
		25-29	331	7	2.1	15	4.5	158	47.7	.	.	1	0.3	281	84.9	319	96.4	57	17.2
		30-34	156	4	2.6	2	1.3	64	41.0	.	.	1	0.6	127	81.4	143	91.7	20	12.8
		35+	65	1	1.5	2	3.1	35	53.8	53	81.5	62	95.4	19	29.2
	Years since diagnosis	5-9	343	4	1.2	21	6.1	264	77.0	1	0.3	1	0.3	275	80.2	317	92.4	103	30.0
		10-14	791	11	1.4	48	6.1	514	65.0	.	.	2	0.3	679	85.8	764	96.6	188	23.8
		15-19	562	9	1.6	22	3.9	239	42.5	513	91.3	550	97.9	66	11.7
		20+	359	12	3.3	3	0.8	128	35.7	315	87.7	350	97.5	37	10.3
	Age at diagnosis	<1	49	.	.	9	18.4	41	83.7	1	2.0	.	.	35	71.4	44	89.8	22	44.9
		1-4	1055	21	2.0	40	3.8	545	51.7	953	90.3	1032	97.8	167	15.8
		5-9	526	10	1.9	13	2.5	278	52.9	470	89.4	517	98.3	75	14.3
		10-14	314	4	1.3	28	8.9	205	65.3	.	.	1	0.3	247	78.7	289	92.0	99	31.5
		15-20	111	1	0.9	4	3.6	76	68.5	.	.	2	1.8	77	69.4	99	89.2	31	27.9
	Treatment	Chemotherapy, no radiation	704	5	0.7	57	8.1	430	61.1	1	0.1	1	0.1	580	82.4	651	92.5	137	19.5
		Chemotherapy and radiation	1344	31	2.3	37	2.8	710	52.8	.	.	2	0.1	1197	89.1	1324	98.5	255	19.0

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: ALL
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		3657	65	1.8	10	0.3	2030	55.5	3	0.1	2	0.1	3393	92.8	3636	99.4	607	16.6
	Age at baseline	<18	1428	17	1.2	8	0.6	989	69.3	2	0.1	1	0.1	1327	92.9	1418	99.3	328	23.0
		18-19	436	7	1.6	1	0.2	221	50.7	1	0.2	.	.	418	95.9	435	99.8	53	12.2
		20-24	863	21	2.4	1	0.1	411	47.6	808	93.6	860	99.7	108	12.5
		25-29	600	15	2.5	.	.	279	46.5	.	.	1	0.2	541	90.2	598	99.7	83	13.8
		30-34	248	4	1.6	.	.	99	39.9	222	89.5	243	98.0	21	8.5
		35+	82	1	1.2	.	.	31	37.8	77	93.9	82	.	14	17.1
	Years since diagnosis	5-9	649	10	1.5	3	0.5	520	80.1	2	0.3	1	0.2	588	90.6	645	99.4	193	29.7
		10-14	1456	15	1.0	6	0.4	939	64.5	.	.	1	0.1	1344	92.3	1449	99.5	301	20.7
		15-19	937	21	2.2	1	0.1	375	40.0	1	0.1	.	.	898	95.8	931	99.4	62	6.6
		20+	615	19	3.1	.	.	196	31.9	563	91.5	611	99.3	51	8.3
	Age at diagnosis	<1	51	39	76.5	47	92.2	50	98.0	15	29.4
		1-4	1949	37	1.9	7	0.4	1030	52.8	2	0.1	.	.	1845	94.7	1938	99.4	277	14.2
		5-9	998	23	2.3	2	0.2	541	54.2	1	0.1	.	.	919	92.1	993	99.5	162	16.2
		10-14	464	5	1.1	1	0.2	291	62.7	.	.	1	0.2	413	89.0	461	99.4	108	23.3
		15-20	195	129	66.2	.	.	1	0.5	169	86.7	194	99.5	45	23.1
	Treatment	Chemotherapy, no radiation	1069	9	0.8	6	0.6	597	55.8	976	91.3	1058	99.0	135	12.6
		Chemotherapy and radiation	2573	56	2.2	4	0.2	1424	55.3	3	0.1	2	0.1	2406	93.5	2564	99.7	470	18.3
Males	All cases		1914	34	1.8	5	0.3	1111	58.0	3	0.2	.	.	1758	91.8	1903	99.4	366	19.1
	Age at baseline	<18	774	10	1.3	4	0.5	557	72.0	2	0.3	.	.	717	92.6	766	99.0	193	24.9
		18-19	238	3	1.3	1	0.4	129	54.2	1	0.4	.	.	225	94.5	237	99.6	42	17.6
		20-24	418	11	2.6	.	.	197	47.1	389	93.1	418	.	58	13.9
		25-29	326	9	2.8	.	.	163	50.0	286	87.7	325	99.7	57	17.5
		30-34	121	1	0.8	.	.	53	43.8	106	87.6	120	99.2	13	10.7
		35+	37	12	32.4	35	94.6	37	.	3	8.1
	Years since diagnosis	5-9	366	6	1.6	2	0.5	303	82.8	2	0.5	.	.	331	90.4	364	99.5	121	33.1
		10-14	780	7	0.9	3	0.4	515	66.0	711	91.2	775	99.4	180	23.1
		15-19	457	13	2.8	.	.	196	42.9	1	0.2	.	.	434	95.0	455	99.6	35	7.7
		20+	311	8	2.6	.	.	97	31.2	282	90.7	309	99.4	30	9.6
	Age at diagnosis	<1	24	18	75.0	22	91.7	23	95.8	6	25.0
		1-4	1023	17	1.7	3	0.3	567	55.4	2	0.2	.	.	964	94.2	1016	99.3	165	16.1
		5-9	525	14	2.7	2	0.4	300	57.1	1	0.2	.	.	479	91.2	522	99.4	110	21.0
		10-14	220	3	1.4	.	.	141	64.1	191	86.8	220	.	56	25.5
		15-20	122	85	69.7	102	83.6	122	.	29	23.8
	Treatment	Chemotherapy, no radiation	495	4	0.8	3	0.6	273	55.2	446	90.1	490	99.0	68	13.7
		Chemotherapy and radiation	1410	30	2.1	2	0.1	834	59.1	3	0.2	.	.	1306	92.6	1405	99.6	298	21.1
Females	All cases		1743	31	1.8	5	0.3	919	52.7	.	.	2	0.1	1635	93.8	1733	99.4	241	13.8

	Age at baseline	<18	654	7	1.1	4	0.6	432	66.1	.	.	1	0.2	610	93.3	652	99.7	135	20.6
		18-19	198	4	2.0	.	.	92	46.5	193	97.5	198	.	11	5.6
		20-24	445	10	2.2	1	0.2	214	48.1	419	94.2	442	99.3	50	11.2
		25-29	274	6	2.2	.	.	116	42.3	.	.	1	0.4	255	93.1	273	99.6	26	9.5
		30-34	127	3	2.4	.	.	46	36.2	116	91.3	123	96.9	8	6.3
		35+	45	1	2.2	.	.	19	42.2	42	93.3	45	.	11	24.4
	Years since diagnosis	5-9	283	4	1.4	1	0.4	217	76.7	.	.	1	0.4	257	90.8	281	99.3	72	25.4
		10-14	676	8	1.2	3	0.4	424	62.7	.	.	1	0.1	633	93.6	674	99.7	121	17.9
		15-19	480	8	1.7	1	0.2	179	37.3	464	96.7	476	99.2	27	5.6
		20+	304	11	3.6	.	.	99	32.6	281	92.4	302	99.3	21	6.9
	Age at diagnosis	<1	27	21	77.8	25	92.6	27	.	9	33.3
		1-4	926	20	2.2	4	0.4	463	50.0	881	95.1	922	99.6	112	12.1
		5-9	473	9	1.9	.	.	241	51.0	440	93.0	471	99.6	52	11.0
		10-14	244	2	0.8	1	0.4	150	61.5	.	.	1	0.4	222	91.0	241	98.8	52	21.3
		15-20	73	44	60.3	.	.	1	1.4	67	91.8	72	98.6	16	21.9
	Treatment	Chemotherapy, no radiation	574	5	0.9	3	0.5	324	56.4	530	92.3	568	99.0	67	11.7
		Chemotherapy and radiation	1163	26	2.2	2	0.2	590	50.7	.	.	2	0.2	1100	94.6	1159	99.7	172	14.8

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: AML
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		322	9	2.8	163	50.6	315	97.8	1	0.3	1	0.3	78	24.2	218	67.7	245	76.1
	Age at baseline	<18	103	1	1.0	74	71.8	100	97.1	1	1.0	.	.	21	20.4	60	58.3	87	84.5
		18-19	40	.	.	19	47.5	38	95.0	10	25.0	27	67.5	31	77.5
		20-24	62	5	8.1	34	54.8	61	98.4	13	21.0	48	77.4	42	67.7
		25-29	66	1	1.5	24	36.4	66	20	30.3	48	72.7	50	75.8	
		30-34	35	1	2.9	9	25.7	34	97.1	.	.	1	2.9	8	22.9	23	65.7	23	65.7
		35+	16	1	6.3	3	18.8	16	6	37.5	12	75.0	12	75.0	
	Years since diagnosis	5-9	70	2	2.9	40	57.1	68	97.1	1	1.4	.	.	9	12.9	37	52.9	54	77.1
		10-14	127	2	1.6	85	66.9	125	98.4	.	.	1	0.8	23	18.1	85	66.9	102	80.3
		15-19	86	3	3.5	33	38.4	85	98.8	31	36.0	68	79.1	65	75.6
		20+	39	2	5.1	5	12.8	37	94.9	15	38.5	28	71.8	24	61.5
	Age at diagnosis	<1	28	.	.	16	57.1	27	96.4	1	3.6	.	.	10	35.7	20	71.4	19	67.9
		1-4	106	1	0.9	65	61.3	103	97.2	25	23.6	69	65.1	85	80.2
		5-9	57	3	5.3	25	43.9	56	98.2	18	31.6	42	73.7	43	75.4
		10-14	74	2	2.7	39	52.7	72	97.3	13	17.6	47	63.5	59	79.7
		15-20	57	3	5.3	18	31.6	57	.	.	.	1	1.8	12	21.1	40	70.2	39	68.4
	Treatment	Chemotherapy, no radiation	166	.	.	87	52.4	163	98.2	1	0.6	1	0.6	42	25.3	90	54.2	114	68.7
		Chemotherapy and radiation	155	9	5.8	75	48.4	151	97.4	36	23.2	128	82.6	130	83.9
Males	All cases		153	5	3.3	75	49.0	151	98.7	31	20.3	102	66.7	116	75.8
	Age at baseline	<18	52	1	1.9	37	71.2	50	96.2	8	15.4	30	57.7	44	84.6
		18-19	19	.	.	8	42.1	19	4	21.1	12	63.2	16	84.2	
		20-24	32	2	6.3	13	40.6	32	6	18.8	25	78.1	21	65.6	
		25-29	27	.	.	9	33.3	27	7	25.9	19	70.4	20	74.1	
		30-34	18	1	5.6	7	38.9	18	4	22.2	13	72.2	11	61.1	
		35+	5	1	20.0	1	20.0	5	2	40.0	3	60.0	4	80.0	
	Years since diagnosis	5-9	41	2	4.9	20	48.8	40	97.6	6	14.6	25	61.0	30	73.2
		10-14	58	.	.	41	70.7	58	8	13.8	38	65.5	47	81.0	
		15-19	39	2	5.1	12	30.8	38	97.4	11	28.2	29	74.4	30	76.9
		20+	15	1	6.7	2	13.3	15	6	40.0	10	66.7	9	60.0	
	Age at diagnosis	<1	11	.	.	8	72.7	11	3	27.3	8	72.7	9	81.8	
		1-4	52	.	.	29	55.8	51	98.1	8	15.4	32	61.5	42	80.8
		5-9	29	2	6.9	12	41.4	28	96.6	10	34.5	20	69.0	23	79.3
		10-14	27	.	.	12	44.4	27	4	14.8	19	70.4	18	66.7	
		15-20	34	3	8.8	14	41.2	34	6	17.6	23	67.6	24	70.6	
	Treatment	Chemotherapy, no radiation	71	.	.	33	46.5	71	15	21.1	35	49.3	48	67.6	
		Chemotherapy and radiation	81	5	6.2	41	50.6	79	97.5	16	19.8	67	82.7	67	82.7
Females	All cases		169	4	2.4	88	52.1	164	97.0	1	0.6	1	0.6	47	27.8	116	68.6	129	76.3

	Age at baseline	<18	51	.	.	37	72.5	50	98.0	1	2.0	.	.	13	25.5	30	58.8	43	84.3
		18-19	21	.	.	11	52.4	19	90.5	6	28.6	15	71.4	15	71.4
		20-24	30	3	10.0	21	70.0	29	96.7	7	23.3	23	76.7	21	70.0
		25-29	39	1	2.6	15	38.5	39	13	33.3	29	74.4	30	76.9
		30-34	17	.	.	2	11.8	16	94.1	.	.	1	5.9	4	23.5	10	58.8	12	70.6
		35+	11	.	.	2	18.2	11	4	36.4	9	81.8	8	72.7
	Years since diagnosis	5-9	29	.	.	20	69.0	28	96.6	1	3.4	.	.	3	10.3	12	41.4	24	82.8
		10-14	69	2	2.9	44	63.8	67	97.1	.	.	1	1.4	15	21.7	47	68.1	55	79.7
		15-19	47	1	2.1	21	44.7	47	20	42.6	39	83.0	35	74.5
		20+	24	1	4.2	3	12.5	22	91.7	9	37.5	18	75.0	15	62.5
	Age at diagnosis	<1	17	.	.	8	47.1	16	94.1	1	5.9	.	.	7	41.2	12	70.6	10	58.8
		1-4	54	1	1.9	36	66.7	52	96.3	17	31.5	37	68.5	43	79.6
		5-9	28	1	3.6	13	46.4	28	8	28.6	22	78.6	20	71.4
		10-14	47	2	4.3	27	57.4	45	95.7	9	19.1	28	59.6	41	87.2
		15-20	23	.	.	4	17.4	23	.	.	.	1	4.3	6	26.1	17	73.9	15	65.2
	Treatment	Chemotherapy, no radiation	95	.	.	54	56.8	92	96.8	1	1.1	1	1.1	27	28.4	55	57.9	66	69.5
		Chemotherapy and radiation	74	4	5.4	34	45.9	72	97.3	20	27.0	61	82.4	63	85.1

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: All CNS
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1663	4	0.2	.	.	95	5.7	13	0.8	.	.	7	0.4	52	3.1	26	1.6
	Age at baseline	<18	503	3	0.6	.	.	59	11.7	3	0.6	.	.	3	0.6	23	4.6	14	2.8
		18-19	142	9	6.4	1	0.7	3	2.1	2	1.4
		20-24	381	1	0.3	.	.	19	5.0	3	0.8	.	.	2	0.5	11	2.9	3	0.8
		25-29	339	8	2.4	5	1.5	.	.	2	0.6	7	2.1	6	1.8
		30-34	209	1	0.5	7	3.3	1	0.5
		35+	89	1	1.1	.	.
	Years since diagnosis	5-9	298	1	0.3	.	.	50	16.8	2	0.7	.	.	3	1.0	16	5.4	6	2.0
		10-14	663	2	0.3	.	.	39	5.9	7	1.1	.	.	2	0.3	16	2.4	20	3.0
		15-19	408	1	0.2	.	.	5	1.2	4	1.0	.	.	2	0.5	10	2.5	.	.
		20+	294	1	0.3	10	3.4	.	.
	Age at diagnosis	<1	87	6	6.9	2	2.3	5	5.7	4	4.6
		1-4	485	1	0.2	.	.	30	6.2	1	0.2	.	.	2	0.4	11	2.3	9	1.9
		5-9	496	3	0.6	.	.	36	7.3	2	0.4	.	.	2	0.4	20	4.1	4	0.8
		10-14	412	18	4.4	6	1.5	.	.	2	0.5	14	3.4	4	1.0
		15-20	183	5	2.8	2	1.1	.	.	1	0.6	2	1.1	5	2.8
	Treatment	Chemotherapy, no radiation	29	3	10.3	1	3.4	1	3.4
		Chemotherapy and radiation	472	4	0.8	.	.	92	19.5	13	2.8	.	.	7	1.5	51	10.8	25	5.3
Males	All cases		912	2	0.2	.	.	63	6.9	9	1.0	.	.	6	0.7	37	4.1	18	2.0
	Age at baseline	<18	275	1	0.4	.	.	39	14.2	2	0.7	.	.	2	0.7	14	5.1	11	4.0
		18-19	79	4	5.1	1	1.3	2	2.5	2	2.5
		20-24	203	1	0.5	.	.	12	5.9	2	1.0	.	.	2	1.0	9	4.5	2	1.0
		25-29	192	8	4.2	4	2.1	.	.	2	1.1	7	3.7	3	1.6
		30-34	115	4	3.5	.	.
		35+	48	1	2.2	.	.
	Years since diagnosis	5-9	169	1	0.6	.	.	32	18.9	2	1.2	.	.	3	1.8	11	6.5	3	1.8
		10-14	361	1	0.3	.	.	28	7.8	5	1.4	.	.	2	0.6	11	3.1	15	4.2
		15-19	226	2	0.9	2	0.9	.	.	1	0.4	7	3.1	.	.
		20+	156	1	0.6	8	5.2	.	.
	Age at diagnosis	<1	51	5	9.8	2	3.9	4	7.8	4	7.8
		1-4	255	19	7.5	1	0.4	6	2.4	7	2.7
		5-9	275	2	0.7	.	.	21	7.7	1	0.4	.	.	2	0.7	16	5.9	3	1.1
		10-14	228	13	5.7	6	2.6	.	.	2	0.9	9	4.0	1	0.4
		15-20	103	5	5.0	1	1.0	2	2.0	3	3.0
	Treatment	Chemotherapy, no radiation	16	1	6.3	1	6.3	1	6.3
		Chemotherapy and radiation	284	2	0.7	.	.	62	21.8	9	3.2	.	.	6	2.1	36	12.7	17	6.0
Females	All cases		751	2	0.3	.	.	32	4.3	4	0.5	.	.	1	0.1	15	2.0	8	1.1

	Age at baseline	<18	228	2	0.9	.	.	20	8.8	1	0.4	.	.	1	0.4	9	3.9	3	1.3
		18-19	63	5	8.1	1	1.6	.	.
		20-24	178	7	3.9	1	0.6	2	1.1	1	0.6
		25-29	147	1	0.7	3	2.1
		30-34	94	1	1.1	3	3.2	1	1.1
		35+	41
	Years since diagnosis	5-9	129	18	14.0	5	3.9	3	2.3
		10-14	302	1	0.3	.	.	11	3.7	2	0.7	5	1.7	5	1.7
		15-19	182	1	0.6	.	.	3	1.7	2	1.1	.	.	1	0.6	3	1.7	.	.
		20+	138	2	1.4	.	.
	Age at diagnosis	<1	36	1	2.8	1	2.8	.	.
		1-4	230	1	0.4	.	.	11	4.8	1	0.4	.	.	1	0.4	5	2.2	2	0.9
		5-9	221	1	0.5	.	.	15	6.8	1	0.5	4	1.8	1	0.5
		10-14	184	5	2.7	5	2.7	3	1.6
		15-20	80	2	2.5	2	2.5
	Treatment	Chemotherapy, no radiation	13	2	15.4
		Chemotherapy and radiation	188	2	1.1	.	.	30	16.0	4	2.1	.	.	1	0.5	15	8.0	8	4.3

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Astrocytomas
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1055	1	0.1	.	.	32	3.0	10	1.0	.	.	2	0.2	12	1.1	18	1.7
	Age at baseline	<18	305	1	0.3	.	.	20	6.6	2	0.7	4	1.3	9	3.0
		18-19	89	1	1.1	1	1.1	2	2.2
		20-24	247	7	2.8	3	1.2	.	.	1	0.4	3	1.2	1	0.4
		25-29	217	4	1.9	5	2.3	.	.	1	0.5	1	0.5	6	2.8
		30-34	135	3	2.2	.	.
		35+	62
	Years since diagnosis	5-9	164	1	0.6	.	.	13	7.9	1	0.6	4	2.4
		10-14	427	17	4.0	5	1.2	.	.	2	0.5	6	1.4	14	3.3
		15-19	247	1	0.4	4	1.6	4	1.6	.	.
		20+	217	1	0.5	2	0.9	.	.
	Age at diagnosis	<1	62	4	6.5	2	3.2	2	3.2	2	3.2
		1-4	325	7	2.2	2	0.6	6	1.8
		5-9	295	1	0.3	.	.	12	4.1	2	0.7	.	.	1	0.3	5	1.7	4	1.4
		10-14	262	8	3.1	5	1.9	.	.	1	0.4	3	1.1	2	0.8
		15-20	111	1	0.9	1	0.9	4	3.6
	Treatment	Chemotherapy, no radiation	17	1	5.9
		Chemotherapy and radiation	200	1	0.5	.	.	31	15.5	10	5.0	.	.	2	1.0	12	6.0	18	9.0
Males	All cases		561	1	0.2	.	.	27	4.8	8	1.4	.	.	2	0.4	8	1.4	14	2.5
	Age at baseline	<18	161	1	0.6	.	.	17	10.6	2	1.2	3	1.9	8	5.0
		18-19	51	1	2.0	2	3.9
		20-24	121	5	4.2	2	1.7	.	.	1	0.8	3	2.5	1	0.8
		25-29	128	4	3.2	4	3.2	.	.	1	0.8	1	0.8	3	2.4
		30-34	68	1	1.5	.	.
		35+	32
	Years since diagnosis	5-9	90	1	1.1	.	.	10	11.1	1	1.1	2	2.2
		10-14	230	15	6.6	5	2.2	.	.	2	0.9	5	2.2	12	5.2
		15-19	127	1	0.8	2	1.6	2	1.6	.	.
		20+	114	1	0.9	1	0.9	.	.
	Age at diagnosis	<1	33	4	12.1	2	6.1	2	6.1	2	6.1
		1-4	169	7	4.1	6	3.6
		5-9	158	1	0.6	.	.	9	5.8	1	0.6	.	.	1	0.6	5	3.2	3	1.9
		10-14	140	6	4.3	5	3.6	.	.	1	0.7	1	0.7	.	.
		15-20	61	1	1.7	3	5.0
	Treatment	Chemotherapy, no radiation	8
		Chemotherapy and radiation	122	1	0.8	.	.	27	22.1	8	6.6	.	.	2	1.6	8	6.6	14	11.5
Females	All cases		494	5	1.0	2	0.4	4	0.8	4	0.8

	Age at baseline	<18	144	3	2.1	1	0.7	1	0.7
		18-19	38	1	2.6	.	.
		20-24	126	2	1.6	1	0.8
		25-29	89	1	1.1	3	3.4
		30-34	67	2	3.0	.	.
		35+	30
	Years since diagnosis	5-9	74	3	4.1	2	2.7
		10-14	197	2	1.0	1	0.5	2	1.0
		15-19	120	2	1.7	2	1.7	.	.
		20+	103	1	1.0	.	.
	Age at diagnosis	<1	29
		1-4	156	2	1.3	.	.
		5-9	137	3	2.2	1	0.7	1	0.7
		10-14	122	2	1.6	2	1.6	2	1.6
		15-20	50	1	2.0	1	2.0
	Treatment	Chemotherapy, no radiation	9	1	11.1
		Chemotherapy and radiation	78	4	5.1	2	2.6	4	5.1	4	5.1

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Medulloblastoma/PNET

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		344	2	0.6	.	.	44	12.9	3	0.9	28	8.2	3	0.9
	Age at baseline	<18	123	1	0.8	.	.	27	22.0	2	1.6	13	10.6	3	2.4
		18-19	27	5	19.2	2	7.7	.	.
		20-24	85	1	1.2	.	.	9	10.6	5	5.9	.	.
		25-29	69	3	4.4	1	1.5	5	7.4	.	.
		30-34	33	3	9.1	.	.
		35+	7
	Years since diagnosis	5-9	74	23	31.1	2	2.7	11	14.9	1	1.4
		10-14	127	2	1.6	.	.	18	14.3	6	4.8	2	1.6
		15-19	107	3	2.8	1	0.9	5	4.7	.	.
		20+	36	6	16.7	.	.
	Age at diagnosis	<1	10	1	10.0	2	20.0	1	10.0
		1-4	103	16	15.5	1	1.0	5	4.9	2	1.9
		5-9	137	2	1.5	.	.	18	13.2	1	0.7	13	9.6	.	.
		10-14	70	7	10.1	1	1.4	7	10.1	.	.
		15-20	24	2	8.3	1	4.2	.	.
	Treatment	Chemotherapy, no radiation	6	1	16.7	1	16.7	.	.
		Chemotherapy and radiation	196	2	1.0	.	.	43	21.9	3	1.5	27	13.8	3	1.5
Males	All cases		203	1	0.5	.	.	28	13.8	3	1.5	23	11.3	2	1.0
	Age at baseline	<18	76	19	25.0	2	2.6	9	11.8	2	2.6
		18-19	15	1	6.7	2	13.3	.	.
		20-24	50	1	2.0	.	.	5	10.0	5	10.0	.	.
		25-29	38	3	7.9	1	2.6	5	13.2	.	.
		30-34	20	2	10.0	.	.
		35+	4
	Years since diagnosis	5-9	48	15	31.3	2	4.2	8	16.7	1	2.1
		10-14	68	1	1.5	.	.	12	17.6	5	7.4	1	1.5
		15-19	67	1	1.5	1	1.5	5	7.5	.	.
		20+	20	5	25.0	.	.
	Age at diagnosis	<1	9	1	11.1	2	22.2	1	11.1
		1-4	59	10	16.9	1	1.7	5	8.5	1	1.7
		5-9	83	1	1.2	.	.	10	12.0	1	1.2	9	10.8	.	.
		10-14	38	5	13.2	1	2.6	6	15.8	.	.
		15-20	14	2	14.3	1	7.1	.	.
	Treatment	Chemotherapy, no radiation	3	1	33.3	1	33.3	.	.
		Chemotherapy and radiation	124	1	0.8	.	.	27	21.8	3	2.4	22	17.7	2	1.6
Females	All cases		141	1	0.7	.	.	16	11.5	5	3.6	1	0.7

	Age at baseline	<18	47	1	2.1	.	.	8	17.0	4	8.5	1	2.1
		18-19	12	4	36.4
		20-24	35	4	11.4
		25-29	31
		30-34	13	1	7.7	.	.
		35+	3
	Years since diagnosis	5-9	26	8	30.8	3	11.5	.	.
		10-14	59	1	1.7	.	.	6	10.3	1	1.7	1	1.7
		15-19	40	2	5.1
		20+	16	1	6.3	.	.
	Age at diagnosis	<1	1
		1-4	44	6	13.6	1	2.3
		5-9	54	1	1.9	.	.	8	15.1	4	7.5	.	.
		10-14	32	2	6.5	1	3.2	.	.
		15-20	10
	Treatment	Chemotherapy, no radiation	3
		Chemotherapy and radiation	72	1	1.4	.	.	16	22.2	5	6.9	1	1.4

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Hodgkin

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5- Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1675	33	2.0	.	.	38	2.3	2	0.1	.	.	2	0.1	29	1.7	3	0.2
	Age at baseline	<18	44	1	2.3	2	4.5	.	.
		18-19	38	3	7.9
		20-24	226	6	2.7	.	.	4	1.8	1	0.4	8	3.6	1	0.4
		25-29	422	10	2.4	.	.	12	2.8	1	0.2	12	2.8	1	0.2
		30-34	474	9	1.9	.	.	9	1.9	5	1.1	.	.
		35+	471	8	1.7	.	.	9	1.9	1	0.2	.	.	1	0.2	2	0.4	1	0.2
	Years since diagnosis	5-9	193	3	1.6	.	.	12	6.2	1	0.5	14	7.3	2	1.0
		10-14	523	7	1.3	.	.	9	1.7	1	0.2	12	2.3	.	.
		15-19	492	11	2.2	.	.	6	1.2	1	0.2	2	0.4	.	.
		20+	467	12	2.6	.	.	11	2.4	1	0.2	1	0.2	1	0.2
	Age at diagnosis	1-4	47
		5-9	211	6	2.8	.	.	5	2.4	2	0.9	.	.
		10-14	577	19	3.3	.	.	11	1.9	5	0.9	.	.
		15-20	840	8	1.0	.	.	22	2.6	2	0.2	.	.	2	0.2	22	2.6	3	0.4
	Treatment	Chemotherapy, no radiation	98	3	3.1	1	1.0	.	.
		Chemotherapy and radiation	1024	33	3.2	.	.	35	3.4	2	0.2	.	.	2	0.2	28	2.7	3	0.3
Males	All cases		891	15	1.7	.	.	29	3.3	2	0.2	16	1.8	3	0.3
	Age at baseline	<18	34	2	5.9	.	.
		18-19	31	3	9.7
		20-24	144	4	2.8	.	.	4	2.8	4	2.8	1	0.7
		25-29	244	4	1.6	.	.	9	3.7	1	0.4	7	2.9	1	0.4
		30-34	237	5	2.1	.	.	8	3.4	2	0.8	.	.
		35+	201	2	1.0	.	.	5	2.5	1	0.5	1	0.5	1	0.5
	Years since diagnosis	5-9	115	2	1.7	.	.	10	8.7	10	8.7	2	1.7
		10-14	281	2	0.7	.	.	7	2.5	1	0.4	4	1.4	.	.
		15-19	270	8	3.0	.	.	6	2.2	1	0.4	.	.
		20+	225	3	1.3	.	.	6	2.7	1	0.4	1	0.4	1	0.4
	Age at diagnosis	1-4	36
		5-9	156	5	3.2	.	.	4	2.6	2	1.3	.	.
		10-14	297	6	2.0	.	.	7	2.4	1	0.3	.	.
		15-20	402	4	1.0	.	.	18	4.5	2	0.5	13	3.2	3	0.7
	Treatment	Chemotherapy, no radiation	52	3	5.8	1	1.9	.	.
		Chemotherapy and radiation	552	15	2.7	.	.	26	4.7	2	0.4	15	2.7	3	0.5
Females	All cases		784	18	2.3	.	.	9	1.2	2	0.3	13	1.7	.	.
	Age at baseline	<18	10	1	10.0
		18-19	7

		20-24	82	2	2.4	1	1.2	4	4.9	.	.
		25-29	178	6	3.4	.	.	3	1.7	5	2.8	.	.
		30-34	237	4	1.7	.	.	1	0.4	3	1.3	.	.
		35+	270	6	2.2	.	.	4	1.5	1	0.4	1	0.4	.	.
	Years since diagnosis	5-9	78	1	1.3	.	.	2	2.6	1	1.3	4	5.1	.	.
		10-14	242	5	2.1	.	.	2	0.8	8	3.3	.	.
		15-19	222	3	1.4	1	0.5	1	0.5	.	.
		20+	242	9	3.7	.	.	5	2.1
	Age at diagnosis	1-4	11
		5-9	55	1	1.8	.	.	1	1.8
		10-14	280	13	4.6	.	.	4	1.4	4	1.4	.	.
		15-20	438	4	0.9	.	.	4	0.9	2	0.5	9	2.1	.	.
	Treatment	Chemotherapy, no radiation	46
		Chemotherapy and radiation	472	18	3.8	.	.	9	1.9	2	0.4	13	2.8	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: NHL
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		925	10	1.1	2	0.2	414	44.8	2	0.2	.	.	274	29.7	792	85.7	229	24.8
	Age at baseline	<18	144	3	2.1	1	0.7	89	61.8	1	0.7	.	.	38	26.4	138	95.8	36	25.0
		18-19	76	1	1.3	.	.	45	59.2	20	26.3	73	96.1	26	34.2
		20-24	198	1	0.5	.	.	87	43.9	1	0.5	.	.	61	30.8	186	93.9	43	21.7
		25-29	227	4	1.8	1	0.4	96	42.3	71	31.3	197	86.8	60	26.4
		30-34	182	71	39.0	61	33.5	151	83.0	46	25.3
		35+	98	1	1.0	.	.	26	26.8	23	23.7	47	48.5	18	18.6
	Years since diagnosis	5-9	110	2	1.8	1	0.9	75	68.2	33	30.0	107	97.3	30	27.3
		10-14	358	4	1.1	1	0.3	177	49.4	2	0.6	.	.	90	25.1	320	89.4	84	23.5
		15-19	278	3	1.1	.	.	112	40.3	84	30.2	248	89.2	82	29.5
		20+	179	1	0.6	.	.	50	28.1	67	37.6	117	65.7	33	18.5
	Age at diagnosis	<1	8	2	25.0	4	50.0	5	62.5	2	25.0
		1-4	150	2	1.3	.	.	74	49.3	1	0.7	.	.	37	24.7	137	91.3	37	24.7
		5-9	280	4	1.4	1	0.4	131	46.8	99	35.4	256	91.4	69	24.6
		10-14	282	3	1.1	1	0.4	127	45.0	1	0.4	.	.	90	31.9	258	91.5	79	28.0
		15-20	205	1	0.5	.	.	80	39.2	44	21.6	136	66.7	42	20.6
	Treatment	Chemotherapy, no radiation	276	3	1.1	.	.	164	59.4	1	0.4	.	.	52	18.8	252	91.3	63	22.8
		Chemotherapy and radiation	598	7	1.2	2	0.3	249	41.6	1	0.2	.	.	222	37.1	539	90.1	166	27.8
Males	All cases		645	7	1.1	1	0.2	286	44.4	181	28.1	558	86.6	153	23.8
	Age at baseline	<18	101	3	3.0	.	.	65	64.4	27	26.7	98	97.0	24	23.8
		18-19	61	1	1.6	.	.	34	55.7	12	19.7	59	96.7	21	34.4
		20-24	136	62	45.6	39	28.7	128	94.1	28	20.6
		25-29	162	3	1.9	1	0.6	69	42.6	48	29.6	145	89.5	43	26.5
		30-34	122	43	35.2	39	32.0	100	82.0	28	23.0
		35+	63	13	21.0	16	25.8	28	45.2	9	14.5
	Years since diagnosis	5-9	84	2	2.4	.	.	58	69.0	25	29.8	83	98.8	23	27.4
		10-14	254	3	1.2	1	0.4	128	50.4	59	23.2	232	91.3	61	24.0
		15-19	177	2	1.1	.	.	67	37.9	50	28.2	161	91.0	47	26.6
		20+	130	33	25.6	47	36.4	82	63.6	22	17.1
	Age at diagnosis	<1	3	1	33.3	1	33.3	.	.
		1-4	103	1	1.0	.	.	54	52.4	23	22.3	93	90.3	27	26.2
		5-9	204	3	1.5	.	.	93	45.6	66	32.4	190	93.1	47	23.0
		10-14	202	3	1.5	1	0.5	91	45.0	61	30.2	186	92.1	57	28.2
		15-20	133	48	36.4	30	22.7	88	66.7	22	16.7
	Treatment	Chemotherapy, no radiation	205	2	1.0	.	.	119	58.0	36	17.6	188	91.7	42	20.5
		Chemotherapy and radiation	401	5	1.2	1	0.2	166	41.4	145	36.2	369	92.0	111	27.7
Females	All cases		280	3	1.1	1	0.4	128	45.7	2	0.7	.	.	93	33.2	234	83.6	76	27.1

	Age at baseline	<18	43	.	.	1	2.3	24	55.8	1	2.3	.	.	11	25.6	40	93.0	12	27.9
		18-19	15	11	73.3	8	53.3	14	93.3	5	33.3
		20-24	62	1	1.6	.	.	25	40.3	1	1.6	.	.	22	35.5	58	93.5	15	24.2
		25-29	65	1	1.5	.	.	27	41.5	23	35.4	52	80.0	17	26.2
		30-34	60	28	46.7	22	36.7	51	85.0	18	30.0
		35+	35	1	2.9	.	.	13	37.1	7	20.0	19	54.3	9	25.7
	Years since diagnosis	5-9	26	.	.	1	3.8	17	65.4	8	30.8	24	92.3	7	26.9
		10-14	104	1	1.0	.	.	49	47.1	2	1.9	.	.	31	29.8	88	84.6	23	22.1
		15-19	101	1	1.0	.	.	45	44.6	34	33.7	87	86.1	35	34.7
		20+	49	1	2.0	.	.	17	34.7	20	40.8	35	71.4	11	22.4
	Age at diagnosis	<1	5	2	40.0	3	60.0	4	80.0	2	40.0
		1-4	47	1	2.1	.	.	20	42.6	1	2.1	.	.	14	29.8	44	93.6	10	21.3
		5-9	76	1	1.3	1	1.3	38	50.0	33	43.4	66	86.8	22	28.9
		10-14	80	36	45.0	1	1.3	.	.	29	36.3	72	90.0	22	27.5
		15-20	72	1	1.4	.	.	32	44.4	14	19.4	48	66.7	20	27.8
	Treatment	Chemotherapy, no radiation	71	1	1.4	.	.	45	63.4	1	1.4	.	.	16	22.5	64	90.1	21	29.6
		Chemotherapy and radiation	197	2	1.0	1	0.5	83	42.1	1	0.5	.	.	77	39.1	170	86.3	55	27.9

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Wilms
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1088	3	0.3	.	.	2	0.2	5	0.5	2	0.2	1	0.1
	Age at baseline	<18	523	1	0.2	2	0.4	1	0.2	1	0.2
		18-19	131	1	0.8
		20-24	249	3	1.2
		25-29	149	1	0.7	.	.	2	1.3	1	0.7	.	.
		30-34	28
		35+	8
	Years since diagnosis	5-9	145	1	0.7
		10-14	436	2	0.5	.	.	1	0.2	2	0.5	2	0.5	1	0.2
		15-19	279	1	0.4	2	0.7
		20+	228	1	0.4
	Age at diagnosis	<1	162	1	0.6	.	.
		1-4	659	1	0.2	.	.	1	0.2	2	0.3
		5-9	225	2	0.9	2	0.9	1	0.4
		10-14	30
		15-20	12	1	8.3	1	8.3	1	8.3	.	.
	Treatment	Chemotherapy, no radiation	369	1	0.3
		Chemotherapy and radiation	701	3	0.4	.	.	2	0.3	4	0.6	2	0.3	1	0.1
Males	All cases		502	1	0.2	.	.	1	0.2	3	0.6	1	0.2	.	.
	Age at baseline	<18	253	1	0.4	2	0.8	1	0.4	.	.
		18-19	58
		20-24	105	1	1.0
		25-29	75	1	1.3
		30-34	9
		35+	2
	Years since diagnosis	5-9	62
		10-14	207	1	0.5	2	1.0	1	0.5	.	.
		15-19	122	1	0.8
		20+	111	1	0.9
	Age at diagnosis	<1	87	1	1.1	.	.
		1-4	309	1	0.3	.	.	1	0.3	1	0.3
		5-9	90	2	2.2
		10-14	12
		15-20	4
	Treatment	Chemotherapy, no radiation	179
		Chemotherapy and radiation	315	1	0.3	.	.	1	0.3	3	1.0	1	0.3	.	.
Females	All cases		586	2	0.3	.	.	1	0.2	2	0.3	1	0.2	1	0.2

	Age at baseline	<18	270	1	0.4
		18-19	73	1	1.4
		20-24	144	2	1.4
		25-29	74	1	1.4	.	.	1	1.4	1	1.4	.	.
		30-34	19
		35+	6
	Years since diagnosis	5-9	83	1	1.2
		10-14	229	1	0.4	.	.	1	0.4	1	0.4	1	0.4
		15-19	157	1	0.6	.	.	.	1	0.6
		20+	117
	Age at diagnosis	<1	75
		1-4	350	1	0.3
		5-9	135	2	1.5	1	0.7
		10-14	18
		15-20	8	1	12.5	1	12.5	1	12.5	.	.
	Treatment	Chemotherapy, no radiation	190	1	0.5
		Chemotherapy and radiation	386	2	0.5	.	.	1	0.3	1	0.3	1	0.3	1	0.3

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Neuroblastoma

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		833	1	0.1	.	.	17	2.0	8	1.0	10	1.2	.	.
	Age at baseline	<18	480	9	1.9	8	1.7	7	1.5	.	.
		18-19	96	1	1.0
		20-24	177	1	0.6	.	.	4	2.3	2	1.1	.	.
		25-29	59	2	3.4	1	1.7	.	.
		30-34	19	1	5.6
		35+	2
	Years since diagnosis	5-9	98	3	3.1	3	3.1	2	2.0	.	.
		10-14	296	6	2.0	4	1.4	5	1.7	.	.
		15-19	249	2	0.8	1	0.4	3	1.2	.	.
		20+	190	1	0.5	.	.	6	3.2
	Age at diagnosis	<1	457	1	0.2	.	.	10	2.2	4	0.9	2	0.4	.	.
		1-4	301	5	1.7	3	1.0	6	2.0	.	.
		5-9	57	1	1.8	1	1.8	1	1.8	.	.
		10-14	12	1	8.3	1	8.3	.	.
		15-20	6
	Treatment	Chemotherapy, no radiation	220	10	4.5	4	1.8
		Chemotherapy and radiation	273	1	0.4	.	.	7	2.6	4	1.5	10	3.7	.	.
Males	All cases		388	1	0.3	.	.	5	1.3	1	0.3	1	0.3	.	.
	Age at baseline	<18	223	2	0.9	1	0.5	1	0.5	.	.
		18-19	43
		20-24	84	1	1.2	.	.	2	2.4
		25-29	26
		30-34	11	1	9.1
		35+	1
	Years since diagnosis	5-9	45	2	4.4	1	2.2
		10-14	140
		15-19	111	1	0.9	.	.
		20+	92	1	1.1	.	.	3	3.3
	Age at diagnosis	<1	232	1	0.4	.	.	3	1.3
		1-4	123	2	1.6	1	0.8	1	0.8	.	.
		5-9	24
		10-14	6
		15-20	3
	Treatment	Chemotherapy, no radiation	101	3	3.0
		Chemotherapy and radiation	126	1	0.8	.	.	2	1.6	1	0.8	1	0.8	.	.
Females	All cases		445	12	2.7	7	1.6	9	2.0	.	.

	Age at baseline	<18	257	7	2.7	7	2.7	6	2.3	.	.
		18-19	53	1	1.9
		20-24	93	2	2.2	2	2.2	.	.
		25-29	33	2	6.1	1	3.0	.	.
		30-34	8
		35+	1
	Years since diagnosis	5-9	53	1	1.9	2	3.8	2	3.8	.	.
		10-14	156	6	3.8	4	2.6	5	3.2	.	.
		15-19	138	2	1.4	1	0.7	2	1.4	.	.
		20+	98	3	3.1
	Age at diagnosis	<1	225	7	3.1	4	1.8	2	0.9	.	.
		1-4	178	3	1.7	2	1.1	5	2.8	.	.
		5-9	33	1	3.1	1	3.1	1	3.1	.	.
		10-14	6	1	16.7	1	16.7	.	.
		15-20	3
	Treatment	Chemotherapy, no radiation	119	7	5.9	4	3.4
		Chemotherapy and radiation	147	5	3.4	3	2.0	9	6.1	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: STS
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1092	5	0.5	.	.	52	4.8	10	0.9	1	0.1	3	0.3	109	10.0	.	.
	Age at baseline	<18	229	27	11.8	2	0.9	.	.	1	0.4	29	12.7	.	.
		18-19	83	2	2.4	.	.	4	4.8	1	1.2	10	12.0	.	.
		20-24	224	2	0.9	.	.	13	5.8	3	1.3	1	0.4	1	0.4	20	8.9	.	.
		25-29	230	1	0.4	.	.	5	2.2	1	0.4	.	.	1	0.4	20	8.7	.	.
		30-34	191	2	1.1	1	0.5	15	7.9	.	.
		35+	135	1	0.7	2	1.5	15	11.2	.	.
	Years since diagnosis	5-9	152	14	9.3	2	1.3	1	0.7	1	0.7	23	15.2	.	.
		10-14	337	2	0.6	.	.	27	8.0	3	0.9	.	.	2	0.6	43	12.8	.	.
		15-19	323	2	0.6	.	.	7	2.2	3	0.9	24	7.4	.	.
		20+	280	1	0.4	.	.	4	1.4	2	0.7	19	6.8	.	.
	Age at diagnosis	<1	80	2	2.5	3	3.8	.	.
		1-4	305	2	0.7	.	.	22	7.2	2	0.7	.	.	1	0.3	26	8.5	.	.
		5-9	223	3	1.3	.	.	18	8.1	2	0.9	25	11.2	.	.
		10-14	231	5	2.2	4	1.7	.	.	2	0.9	23	10.0	.	.
		15-20	253	5	2.0	2	0.8	1	0.4	.	.	32	12.7	.	.
	Treatment	Chemotherapy, no radiation	230	1	0.4	.	.	2	0.9	2	0.9	.	.	2	0.9	23	10.0	.	.
		Chemotherapy and radiation	631	4	0.6	.	.	50	7.9	8	1.3	1	0.2	1	0.2	86	13.6	.	.
Males	All cases		563	2	0.4	.	.	30	5.3	5	0.9	1	0.2	2	0.4	63	11.2	.	.
	Age at baseline	<18	127	14	11.0	1	0.8	.	.	1	0.8	16	12.6	.	.
		18-19	42	1	2.4	.	.	2	4.8	1	2.4	8	19.0	.	.
		20-24	124	7	5.6	1	0.8	1	0.8	.	.	9	7.3	.	.
		25-29	112	1	0.9	.	.	4	3.6	1	0.9	14	12.5	.	.
		30-34	96	2	2.1	1	1.1	8	8.4	.	.
		35+	62	1	1.6	1	1.6	8	12.9	.	.
	Years since diagnosis	5-9	80	10	12.5	1	1.3	1	1.3	.	.	13	16.3	.	.
		10-14	176	1	0.6	.	.	14	8.0	2	1.1	.	.	2	1.1	28	15.9	.	.
		15-19	157	3	1.9	1	0.6	11	7.0	.	.
		20+	150	1	0.7	.	.	3	2.0	1	0.7	11	7.4	.	.
	Age at diagnosis	<1	34	1	2.9
		1-4	183	1	0.5	.	.	11	6.0	1	0.5	.	.	1	0.5	17	9.3	.	.
		5-9	120	1	0.8	.	.	9	7.5	1	0.8	13	10.8	.	.
		10-14	114	4	3.5	2	1.8	.	.	1	0.9	17	15.0	.	.
		15-20	112	5	4.5	1	0.9	1	0.9	.	.	16	14.3	.	.
	Treatment	Chemotherapy, no radiation	127	2	1.6	1	0.8	10	7.9	.	.
		Chemotherapy and radiation	331	2	0.6	.	.	28	8.5	5	1.5	1	0.3	1	0.3	53	16.0	.	.
Females	All cases		529	3	0.6	.	.	22	4.2	5	0.9	.	.	1	0.2	46	8.7	.	.

	Age at baseline	<18	102	13	12.9	1	1.0	13	12.9	.	.
		18-19	41	1	2.4	.	.	2	4.9	2	4.9	.	.
		20-24	100	2	2.0	.	.	6	6.0	2	2.0	.	.	1	1.0	11	11.0	.	.
		25-29	118	1	0.8	1	0.8	6	5.1	.	.
		30-34	95	7	7.4	.	.
		35+	73	1	1.4	7	9.7	.	.
	Years since diagnosis	5-9	72	4	5.6	1	1.4	.	.	1	1.4	10	14.1	.	.
		10-14	161	1	0.6	.	.	13	8.1	1	0.6	15	9.3	.	.
		15-19	166	2	1.2	.	.	4	2.4	2	1.2	13	7.8	.	.
		20+	130	1	0.8	1	0.8	8	6.2	.	.
	Age at diagnosis	<1	46	1	2.2	3	6.5	.	.
		1-4	122	1	0.8	.	.	11	9.0	1	0.8	9	7.4	.	.
		5-9	103	2	1.9	.	.	9	8.7	1	1.0	12	11.7	.	.
		10-14	117	1	0.9	2	1.7	.	.	1	0.9	6	5.2	.	.
		15-20	141	1	0.7	16	11.4	.	.
	Treatment	Chemotherapy, no radiation	103	1	1.0	2	1.9	.	.	1	1.0	13	12.6	.	.
		Chemotherapy and radiation	300	2	0.7	.	.	22	7.3	3	1.0	33	11.0	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: All bone
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1044	2	0.2	.	.	11	1.1	24	2.3	549	52.6	.	.
	Age at baseline	<18	47	1	2.1	3	6.4	19	40.4	.	.
		18-19	43	4	9.3	3	7.0	21	48.8	.	.
		20-24	211	4	1.9	5	2.4	121	57.3	.	.
		25-29	266	1	0.4	4	1.5	147	55.3	.	.
		30-34	285	2	0.7	.	.	1	0.4	8	2.8	151	53.0	.	.
		35+	192	1	0.5	90	46.9	.	.
	Years since diagnosis	5-9	152	7	4.6	7	4.6	92	60.5	.	.
		10-14	357	1	0.3	6	1.7	195	54.6	.	.
		15-19	331	2	0.6	.	.	1	0.3	9	2.7	180	54.4	.	.
		20+	204	2	1.0	2	1.0	82	40.2	.	.
	Age at diagnosis	<1	1
		1-4	35	1	2.9	2	5.7	12	34.3	.	.
		5-9	176	5	2.8	5	2.8	68	38.6	.	.
		10-14	395	3	0.8	8	2.0	231	58.5	.	.
		15-20	437	2	0.5	.	.	2	0.5	9	2.1	238	54.5	.	.
	Treatment	Chemotherapy, no radiation	567	1	0.2	439	77.4	.	.
		Chemotherapy and radiation	370	1	0.3	.	.	11	3.0	24	6.5	108	29.2	.	.
Males	All cases		528	1	0.2	.	.	5	0.9	14	2.7	291	55.1	.	.
	Age at baseline	<18	24	1	4.2	1	4.2	11	45.8	.	.
		18-19	24	3	12.5	3	12.5	10	41.7	.	.
		20-24	99	1	1.0	1	1.0	53	53.5	.	.
		25-29	137	2	1.5	79	57.7	.	.
		30-34	143	1	0.7	6	4.2	83	58.0	.	.
		35+	101	1	1.0	55	54.5	.	.
	Years since diagnosis	5-9	77	5	6.5	5	6.5	45	58.4	.	.
		10-14	188	5	2.7	108	57.4	.	.
		15-19	167	1	0.6	3	1.8	95	56.9	.	.
		20+	96	1	1.0	43	44.8	.	.
	Age at diagnosis	<1	1
		1-4	16	5	31.3	.	.
		5-9	96	2	2.1	1	1.0	39	40.6	.	.
		10-14	178	2	1.1	6	3.4	102	57.3	.	.
		15-20	237	1	0.4	.	.	1	0.4	7	3.0	145	61.2	.	.
	Treatment	Chemotherapy, no radiation	292	228	78.1	.	.
		Chemotherapy and radiation	190	1	0.5	.	.	5	2.6	14	7.4	61	32.1	.	.
Females	All cases		516	1	0.2	.	.	6	1.2	10	1.9	258	50.0	.	.

	Age at baseline	<18	23	2	8.7	8	34.8	.	.
		18-19	19	.	.	.	1	5.3	11	57.9	.	.
		20-24	112	.	.	.	3	2.7	4	3.6	68	60.7	.	.
		25-29	129	.	.	.	1	0.8	2	1.6	68	52.7	.	.
		30-34	142	1	0.7	.	1	0.7	2	1.4	68	47.9	.	.
		35+	91	35	38.5	.	.
	Years since diagnosis	5-9	75	.	.	.	2	2.7	2	2.7	47	62.7	.	.
		10-14	169	.	.	.	1	0.6	1	0.6	87	51.5	.	.
		15-19	164	1	0.6	.	1	0.6	6	3.7	85	51.8	.	.
		20+	108	.	.	.	2	1.9	1	0.9	39	36.1	.	.
	Age at diagnosis	1-4	19	.	.	.	1	5.3	2	10.5	7	36.8	.	.
		5-9	80	.	.	.	3	3.8	4	5.0	29	36.3	.	.
		10-14	217	.	.	.	1	0.5	2	0.9	129	59.4	.	.
		15-20	200	1	0.5	.	1	0.5	2	1.0	93	46.5	.	.
	Treatment	Chemotherapy, no radiation	275	1	0.4	211	76.7	.	.
		Chemotherapy and radiation	180	.	.	.	6	3.3	10	5.6	47	26.1	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Ewings
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%		
Both sexes	All cases		360	10	2.8	21	5.8	59	16.4	.	.
	Age at baseline	<18	31	1	3.2	3	9.7	5	16.1	.	.
		18-19	23	4	17.4	2	8.7	6	26.1	.	.
		20-24	94	3	3.2	5	5.3	19	20.2	.	.
		25-29	91	1	1.1	4	4.4	14	15.4	.	.
		30-34	81	1	1.2	7	8.6	10	12.3	.	.
		35+	40	5	12.5	.	.
	Years since diagnosis	5-9	67	6	9.0	6	9.0	15	22.4	.	.
		10-14	126	1	0.8	6	4.8	29	23.0	.	.
		15-19	107	1	0.9	8	7.5	12	11.2	.	.
		20+	60	2	3.3	1	1.7	3	5.0	.	.
	Age at diagnosis	<1	1
		1-4	23	1	4.3	2	8.7	3	13.0	.	.
		5-9	95	5	5.3	5	5.3	9	9.5	.	.
		10-14	132	3	2.3	7	5.3	22	16.7	.	.
		15-20	109	1	0.9	7	6.4	25	22.9	.	.
	Treatment	Chemotherapy, no radiation	70	15	21.4	.	.
		Chemotherapy and radiation	288	10	3.5	21	7.3	44	15.3	.	.
Males	All cases		186	5	2.7	11	5.9	31	16.7	.	.
	Age at baseline	<18	15	1	6.7	1	6.7	2	13.3	.	.
		18-19	14	3	21.4	2	14.3	3	21.4	.	.
		20-24	50	1	2.0	1	2.0	11	22.0	.	.
		25-29	44	2	4.5	6	13.6	.	.
		30-34	42	5	11.9	7	16.7	.	.
		35+	21	2	9.5	.	.
	Years since diagnosis	5-9	38	5	13.2	4	10.5	8	21.1	.	.
		10-14	62	5	8.1	14	22.6	.	.
		15-19	56	2	3.6	7	12.5	.	.
		20+	30	2	6.7	.	.
	Age at diagnosis	<1	1
		1-4	12	2	16.7	.	.
		5-9	50	2	4.0	1	2.0	5	10.0	.	.
		10-14	68	2	2.9	5	7.4	10	14.7	.	.
		15-20	55	1	1.8	5	9.1	14	25.5	.	.
	Treatment	Chemotherapy, no radiation	39	9	23.1	.	.
		Chemotherapy and radiation	146	5	3.4	11	7.5	22	15.1	.	.
Females	All cases		174	5	2.9	10	5.7	28	16.1	.	.

	Age at baseline	<18	16	2	12.5	3	18.8	.	.
		18-19	9	1	11.1	3	33.3	.	.
		20-24	44	2	4.5	4	9.1	8	18.2	.	.
		25-29	47	1	2.1	2	4.3	8	17.0	.	.
		30-34	39	1	2.6	2	5.1	3	7.7	.	.
		35+	19	3	15.8	.	.
	Years since diagnosis	5-9	29	1	3.4	2	6.9	7	24.1	.	.
		10-14	64	1	1.6	1	1.6	15	23.4	.	.
		15-19	51	1	2.0	6	11.8	5	9.8	.	.
		20+	30	2	6.7	1	3.3	1	3.3	.	.
	Age at diagnosis	1-4	11	1	9.1	2	18.2	1	9.1	.	.
		5-9	45	3	6.7	4	8.9	4	8.9	.	.
		10-14	64	1	1.6	2	3.1	12	18.8	.	.
		15-20	54	2	3.7	11	20.4	.	.
	Treatment	Chemotherapy, no radiation	31	6	19.4	.	.
		Chemotherapy and radiation	142	5	3.5	10	7.0	22	15.5	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - AntiMetabolites: Osteosarcoma
[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)		Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		638	1	0.2	3	0.5	487	76.3	.	.
	Age at baseline	<18	14	14	.	.	.
		18-19	18	1	5.6	15	83.3	.	.
		20-24	110	100	90.9	.	.
		25-29	166	132	79.5	.	.
		30-34	192	1	0.5	.	.	.	1	0.5	141	73.4	.	.	
		35+	138	1	0.7	85	61.6	.	.	
	Years since diagnosis	5-9	79	1	1.3	75	94.9	.	.	
		10-14	215	165	76.7	.	.	
		15-19	213	1	0.5	.	.	.	1	0.5	168	78.9	.	.	
		20+	131	1	0.8	79	60.3	.	.	
	Age at diagnosis	1-4	10	9	90.0	.	.	
		5-9	72	59	81.9	.	.	
		10-14	254	1	0.4	208	81.9	.	.	
		15-20	302	1	0.3	.	.	.	2	0.7	211	69.9	.	.	
	Treatment	Chemotherapy, no radiation	492	1	0.2	423	86.0	.	.	
		Chemotherapy and radiation	74	3	4.1	62	83.8	.	.	
Males	All cases		320	3	0.9	259	80.9	.	.	
	Age at baseline	<18	9	9	.	.	.	
		18-19	8	1	12.5	7	87.5	.	.	
		20-24	46	42	91.3	.	.	
		25-29	88	72	81.8	.	.	
		30-34	94	1	1.1	76	80.9	.	.	
		35+	75	1	1.3	53	70.7	.	.	
	Years since diagnosis	5-9	37	1	2.7	36	97.3	.	.	
		10-14	119	94	79.0	.	.	
		15-19	104	1	1.0	88	84.6	.	.	
		20+	60	1	1.7	41	68.3	.	.	
	Age at diagnosis	1-4	3	3	.	.	.	
		5-9	39	34	87.2	.	.	
		10-14	108	1	0.9	92	85.2	.	.	
		15-20	170	2	1.2	130	76.5	.	.	
	Treatment	Chemotherapy, no radiation	251	219	87.3	.	.	
		Chemotherapy and radiation	41	3	7.3	38	92.7	.	.	
Females	All cases		318	1	0.3	228	71.7	.	.	
	Age at baseline	<18	5	5	.	.	.	
		18-19	10	8	80.0	.	.	

		20-24	64	58	90.6	.	.
		25-29	78	60	76.9	.	.
		30-34	98	1	1.0	65	66.3	.	.
		35+	63	32	50.8	.	.
	Years since diagnosis	5-9	42	39	92.9	.	.
		10-14	96	71	74.0	.	.
		15-19	109	1	0.9	80	73.4	.	.
		20+	71	38	53.5	.	.
	Age at diagnosis	1-4	7	6	85.7	.	.
		5-9	33	25	75.8	.	.
		10-14	146	116	79.5	.	.
		15-20	132	1	0.8	81	61.4	.	.
	Treatment	Chemotherapy, no radiation	241	1	0.4	204	84.6	.	.
		Chemotherapy and radiation	33	24	72.7	.	.

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.